Fig. 1: Clinical implementation of a computational EGFR biomarker.
From: Real-world deployment of a fine-tuned pathology foundation model for lung cancer biomarker detection
In the standard clinical workflow for patients with LUAD, rapid tests for EGFR and other biomarkers are performed, reducing the tissue available for NGS and leading to up to one-quarter of the cases being unsuitable for NGS. By contrast, the clinical application of the proposed EGFR biomarker will allow a drastic reduction in the number of cases unsuitable for NGS. As soon as slides are digitized, the computational biomarker can be calculated and may be available to the pathologist before they review the case and sign it out. Based on the model’s outputs, the rapid test may be avoided, increasing the tissue available for NGS.
